253 Assessed for eligibility
   101 Excluded
      89 Did not meet inclusion criteria
      12 Refused to participate
   152 Enrolled and assigned
   86 Allocated to AC-1202
      3 Lost to follow-up
      35 Discontinued
         20 Adverse events
         8 Withdrew consent
         2 Perceived lack of efficacy
         1 Protocol violation
         1 Relocation
         3 Other
      Of these 38, 9 lacked a post-Baseline visit and were not analyzed for efficacy
   66 Allocated to placebo
      2 Lost to follow-up
      12 Discontinued
         4 Adverse events
         5 Withdrew consent
         2 Perceived lack of efficacy
         1 Protocol violation
         0 Other
      Of these 14, 3 lacked a post-Baseline visit and are were not analyzed for efficacy
   77 Analyzed
   63 Analyzed
   ITT Population
   67 APOE Genotyped
   57 APOE Genotyped
   ITT/Genotyped Population